Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion
Expanded deal focuses on Synaffix’s GlycoConnect™ site-specific ADC bioconjugation technology and adds license options for six new programs to existing deal Mersana currently developing two programs based on GlycoConnect™ site-specific ADC bioconjugation technology (XMT-1592 and XMT-1660) AMSTERDAM, NETHERLANDS, November 30, 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the […]
